Highlander Partners’s Reata Pharmaceuticals RETA Stock Holding History
Bought
Maintained
Sold
Other funds holding RETA
CI
Highlander Partners's RETA Position: Q1 2022 in Review
Highlander Partners sold out of Reata Pharmaceuticals (RETA) in Q1 2022, closing a stake of 27,600 shares — an estimated $728K sold.
Highlander Partners first reported a position in RETA in Q4 2021 and held it in 1 quarter. The position peaked at $728K in Q4 2021. 147 funds tracked by Wall St. Rank hold RETA as of Q1 2022.
- Highlander Partners reported no remaining Reata Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
- Highlander Partners sold 27,600 Reata Pharmaceuticals shares in Q1 2022, an estimated $728K.
- Highlander Partners first reported a position in Reata Pharmaceuticals in Q4 2021 and held it in 1 quarter.
- Highlander Partners's Reata Pharmaceuticals position peaked at $728K in Q4 2021.
- 147 funds tracked by Wall St. Rank held Reata Pharmaceuticals as of Q1 2022.
Based on Highlander Partners's 13F filing for Q1 2022, filed 27 Apr 2022.